Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open label extension achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) at Week 56 For participants who achieved disease clearance and switched to proactive twice weekly application of roflumilast cream, the median duration o ...

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream 0.15% in both the 4-week parent study and the 52-week open label extension achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) at Week 56 For participants who achieved disease clearance and switched to proactive twice weekly application of roflumilast cream, the median duration o ...

WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 57,500 restricted stock units of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, wit ...

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $9.20, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.50 indicates a 101.1% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $4.81. While the lowest estimate of $11 indicates a 19.6% increase from the current price level, the most optimist ...

财务数据和关键指标变化 - 第一季度净收入为2160万美元,较上一季度增长59%,较上年同期增长675% [59][60] - 研发费用为2380万美元,较上年同期大幅下降,但与上一季度持平 [62] - 销售及一般管理费用为5480万美元,较上一季度和上年同期均有所增加 [63] - 公司现金及可流动资产总额为4.04亿美元,为后续商业化和管线推进提供了充足资金支持 [66][67] 各条业务线数据和关键指标变化 - ZORYVE乳膏在银屑病领域的处方量持续增长,第一季度较上一季度增长8%,较上年同期增长120% [24] - ZORYVE泡沫在seborrheic dermatitis领域的处方量在上市3个月内已达4.6万个,增长势头强劲 [28][29] - 公司正在努力提高ZORYVE乳膏和泡沫的保险覆盖率,目前分别达到75%和50%以上 [37][38] 各个市场数据和关键指标变化 - 公司正在积极推进Medicare和Medicaid的准入工作,预计到2024年底将实现更广泛的覆盖 [72][74] - 公司还在与主要医保公司进行合作谈判,希望进一步提高ZORYVE产品的保险覆盖率 [36][37] 公司战略和发展方向及行业竞争 - 公司正在推进ZORYVE在银屑病、seborrheic dermatitis和湿疹三大适应症的商业化,形成产品组合优势 [41][42][43] - 公司正在寻求与主要医疗保险公司和初级护理领域的合作伙伴,以进一步扩大ZORYVE的覆盖面 [90][94] - 公司的定价和准入策略有利于在Medicare和Medicaid等公共医保体系中获得较好的覆盖 [81][99] 管理层对经营环境和未来前景的评论 - 管理层对公司在银屑病、seborrheic dermatitis领域的商业化进展表示满意,并对即将到来的湿疹适应症获批持乐观态度 [12][17][21] - 管理层认为公司目前的资金实力能够支持现有产品的商业化和管线的推进 [66][67] - 管理层对公司未来的收入增长和毛利率水平持乐观态度 [38][99] 问答环节重要的提问和回答 问题1 **Serge Belanger 提问** 对于即将获批的湿疹适应症,公司预期的标签是否会包括瘙痒等症状数据,以及覆盖范围是否会包括轻中重度湿疹 [72] **Patrick Burnett 回答** 公司预期湿疹适应症的标签会与现有银屑病乳膏标签类似,包括瘙痒等症状数据,覆盖轻中度湿疹患者 [74][75] 问题2 **Seamus Fernandez 提问** 公司对ZORYVE在湿疹领域的市场机会和渗透率目标如何评估,与Opzelura等竞品相比有何优势 [79] **Patrick Burnett 回答** 公司预计湿疹适应症的渗透率不会像seborrheic dermatitis那样快速,但有望超过银屑病,因为医生已有ZORYVE的使用经验,以及产品组合优势 [84][85] 问题3 **Uy Ear 提问** 公司是否预计Medicare和Medicaid的覆盖会对ZORYVE的毛利率产生重大影响,以及公司的新分销计划如何提高毛利率 [98] **David Topper 回答** 公司预计Medicare和Medicaid的覆盖不会对毛利率产生重大影响,因为定价策略和准入策略较为合理。新的分销计划通过直接向药房提供未获保险报销的处方,有助于进一步提高毛利率 [99][100]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2974255 (State or Other Juris ...

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update • First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23 • Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 60 percent range • Sustained growth in demand for cream and remarkable uptake of foam launched in January • July 7 ...

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation data Crodafos™ CES, used in ZORYVE foam, is suitable for a wide variety of skin and hair types Findings from this formulation review underscore the suitability of ZORYVE foam for use on all affected areas of the body, and all hair types, in the management of seborrheic dermatitis WESTLAKE VI ...

WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and the pre ...

ARQT股价走势 - Arcutis Biotherapeutics, Inc. (ARQT)最近股价走势熊市，过去两周下跌了6.5%[1] - Hammer图案的形成表明股价可能很快见底并出现趋势反转，基本面上，华尔街分析师普遍提高了对该公司的盈利预期[2] - Hammer图案是蜡烛图中的一种常见价格模式，当在下跌趋势底部出现时，表明空头可能失去对价格的控制，有望出现潜在的趋势反转[3] ARQT盈利预期 - ARQT近期盈利预期修订呈上升趋势，这是基本面上的一个积极指标，因为盈利预期修订趋势与股价短期走势强相关[7] - 当前年度的共识EPS预期在过去30天内增长了6%，这意味着覆盖ARQT的华尔街分析师普遍认为公司有望报告比之前预测更好的盈利[8] - ARQT目前的Zacks排名为2（买入），这意味着它在我们基于盈利预期修订趋势和EPS惊喜排名的4000多只股票中处于前20%[9]